Indian Health Minister Asks Novartis to Stand Down On Gleevec Patent Fight
This article was originally published in PharmAsia News
Executive Summary
The Indian health minister Anbumani Ramadoss urged Novartis earlier this month to end its legal bid to win patent protection for its oncologic Gleevec, or he said the government may override existing patents for vitally necessary drugs by issuing licenses that allow Indian generic manufacturers to produce cheaper versions in the interest of public health